2 pages

English

DRAFT FOR COMMENT APPROVAL

Ontea - Doug

Le téléchargement nécessite un accès à la bibliothèque YouScribe
Tout savoir sur nos offres

2 pages

English

Le téléchargement nécessite un accès à la bibliothèque YouScribe
Tout savoir sur nos offres

A propos
Informations
Extrait

Description

NEWS Champions Biotechnology Partners with Gradalis Inc. and Mary Crowley Cancer Research Center to Develop Personalized Vaccines for Cancer Patients February 03, 2009 – Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established a collaboration with Gradalis Inc. and Mary Crowley Cancer Research Center (MCCRC). The team will seek an Investigational New Drug (IND) permission from the U.S. Food and Drug Administration (FDA) to utilize Champions Biotechnology’s Biomerk Tumorgraft™ technology to develop personalized vaccines for cancer patients. Each vaccine is engineered to treat the patient’s specific cancer because it is developed from the patient’s own tumor. “The close correlation between Biomerk Tumorgrafts™ and the human tumor they are derived from provide the basis for our predictive preclinical platform. This technology also enables us, in collaboration with Gradalis, to develop personalized vaccines for cancer patients,” said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. “Personalized vaccines offer a novel treatment option that is customized to each individual’s unique cancer but can rarely be produced due to insufficient cells from accessible tumor tissue. We are pleased to enter into this agreement with Gradalis and MCCRC that leverages the value of our unique platform ...

Informations

Publié par	Ontea
Nombre de lectures	59
Langue	English

Extrait

NEWS

Champions Biotechnology Partners with Gradalis Inc. and Mary Crowley Cancer Research

Center to Develop Personalized Vaccines for Cancer Patients

February 03, 2009 – Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in

the development of advanced preclinical platforms and tumor specific data to enhance the value of

oncology drugs, has established a collaboration with Gradalis Inc. and Mary Crowley Cancer Research

Center (MCCRC). The team will seek an Investigational New Drug (IND) permission from the U.S. Food

and Drug Administration (FDA) to utilize Champions Biotechnology’s Biomerk Tumorgraft™ technology

to develop personalized vaccines for cancer patients. Each vaccine is engineered to treat the patient’s

specific cancer because it is developed from the patient’s own tumor.

“The close correlation between Biomerk Tumorgrafts™ and the human tumor they are derived from

provide the basis for our predictive preclinical platform. This technology also enables us, in

collaboration with Gradalis, to develop personalized vaccines for cancer patients,” said Doug Burkett,

Ph.D., President of Champions Biotechnology, Inc. “Personalized vaccines offer a novel treatment

option that is customized to each individual’s unique cancer but can rarely be produced due to

insufficient cells from accessible tumor tissue. We are pleased to enter into this agreement with Gradalis

and MCCRC that leverages the value of our unique platform.”

Under the terms of the agreement Gradalis Inc. will work toward the IND that is required to begin

administering the individualized vaccine to patients at MCCRC in a Phase I clinical trial. Champions

Biotechnology anticipates that the collaboration will result in a new, near term option for the growing

number of physicians that are taking advantage of the Company’s Personalized Oncology services and a

significant opportunity for the Company in any future commercialization of the technology.

For more information regarding Champions Biotechnology’s growing business and recent news, please

visit

www.championsbiotechnology.com

About MCCRC

The Mary Crowley Cancer Research Center is a national leader in cancer research with a clearly defined

program and commitment to excellence to dramatically alter strategies of cancer treatment. MCCRC’s

mission is to pioneer personalized options for all cancer patients through gene-targeted therapies, cell

based therapies, and vaccines.

Mary Crowley is dedicated to achieving a paradigm shift in cancer care, in which personalized molecular

medicine will ultimately transform the way patients are treated. Mary Crowley, through research focus

and a patient-centric care model, has implemented over 140 FDA approved clinical trials, with more

than 300 investigational agents, resulting in hundreds of peer-reviewed publications. Thousands of

patients have participated in investigational studies at Mary Crowley.

About Gradalis Inc.

Gradalis is a vertically integrated biotechnology company committed to developing core technologies and

delivering therapeutics that offer safer and more effective treatments for cancer, muscular dystrophy and

other critical illnesses. From the discovery and research phase to development and commercialization,

Gradalis is accelerating a pipeline of breakthrough therapies that will transform the lives of the patients

who need them.

About Champions Biotechnology, Inc.

Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and

tumor specific data to enhance and accelerate the value of oncology drugs. The Company’s Preclinical

Platform is a novel approach based upon the implantation of primary human tumors in immune

deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts™) in a

manner that preserves the biological characteristics of the original human tumor. Early studies suggest

that unlike traditional xenografts, these Tumorgrafts closely reflect human cancer biology and their

response to drugs is predictive of clinical outcomes in cancer patients.

Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop

a portfolio of novel therapeutic candidates through pre-clinical trials. As drugs progress through this

early stage of development, the Company plans to sell, partner or license them to pharmaceutical

and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical

platform and tumor specific data to physicians for personalized patient care and to Companies for

evaluation of oncology drugs in models that integrate prognostic testing with biomarker discovery.

This press release contains "forward-looking statements" (within the meaning of the Private Securities

Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Biotechnology generally

uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar

expressions to identify forward-looking statements. One should not place undue reliance on these

forward-looking statements. The Company's actual results could differ materially from those anticipated

in the forward-looking statements for many unforeseen factors. See Champions Biotechnology's Form

10-KSB for the fiscal year ended April 30, 2008 for a discussion of such risks, uncertainties and other

factors. Although the Company believes the expectations reflected in the forward-looking statements are

reasonable, they relate only to events as of the date on which the statements are made, and Champions

Biotechnology's future results, levels of activity, performance or achievements, including but not limited

to obtaining the IND referenced above or any resulting opportunities, may not meet these expectations.

The Company does not intend to update any of the forward-looking statements after the date of this

press release to conform these statements to actual results or to changes in Champions Biotechnology's

expectations, except as required by law.

CHAMPIONS BIOTECHNOLOGY, INC. WEB SITE:

www.championsbiotechnology.com

Contact:

The Investor Relations Group, Inc.

James Carbonara, 212-825-3210

Public Relations:

Susan Morgenbesser / Janet Vasquez, 212-825-3210

Univers
Ebooks
Livres audio
Presse
Podcasts
BD
Documents

DRAFT FOR COMMENT APPROVAL

YouScribe

Le catalogue

Le service

Les conditions